![Comparative Outcomes Analysis on Low-Risk Pregnancies with or without Labor Induction](https://trinetx.com/wp-content/uploads/2023/05/2023-ISPOR_KD_PregnancyOutcomes_web-1080x675.png)
![Comparative Outcomes Analysis on Low-Risk Pregnancies with or without Labor Induction](https://trinetx.com/wp-content/uploads/2023/05/2023-ISPOR_KD_PregnancyOutcomes_web-1080x675.png)
![An Exploratory Analysis Of Real-World Data For Assessing Patient Characteristics, Region, Stage, and PD-L1 Healthcare Utilization Among U.S. Patients With Advanced Lung Cancer](https://trinetx.com/wp-content/uploads/2023/05/2023-ISPOR_GA_NSCLC_Web-1080x675.png)
An Exploratory Analysis Of Real-World Data For Assessing Patient Characteristics, Region, Stage, and PD-L1 Healthcare Utilization Among U.S. Patients With Advanced Lung Cancer
![Hepatitis C Medications: Analysis of Adverse Drug Events and Poor Patient Outcomes](https://trinetx.com/wp-content/uploads/2024/01/AHA_ISPOR_Wash_DC_May_2016_Poster_17MAY2016_Final_Final-1080x675.jpg)
Hepatitis C Medications: Analysis of Adverse Drug Events and Poor Patient Outcomes
![Calculating the costs of adverse drug reactions from post-marketing data: Implications for outcomes research](https://trinetx.com/wp-content/uploads/2024/01/ISPOR_Poster_08MAY2015_1-1-1080x675.jpg)
Calculating the costs of adverse drug reactions from post-marketing data: Implications for outcomes research
![Real-world patient characteristics and survival outcomes of lenalidomide-refractory vs. lenalidomide-exposed RRMM patients in the HONEUR federated data network](https://trinetx.com/wp-content/uploads/2024/01/2023_05_29_HONEUR_EHA_poster__FINAL_-1080x675.jpg)